Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
[EN] BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLE BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE/PHOSPHODIESTÉRASE 1
申请人:RIBOSCIENCE LLC
公开号:WO2020210649A1
公开(公告)日:2020-10-15
The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
[EN] SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] BENZIMIDAZOLE CARBOXAMIDES SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
申请人:BIAL BIOTECH INVEST INC
公开号:WO2021055591A1
公开(公告)日:2021-03-25
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.
AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM
申请人:McKittrick A. Brian
公开号:US20080070888A1
公开(公告)日:2008-03-20
Disclosed are compounds of the formula
wherein Z
1
is —CH
2
— or —C(O)—, R
4
and R
5
are carbon chains (and optionally, together can form a C
2
bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R
2
is heteroaryl, and R
1
and R
3
are as defined herein. Also disclosed are methods of treating pain using a compound of formula I.
揭示了以下公式的化合物
其中 Z
1
为—CH
2
—或—C(O)—,R
4
和 R
5
为碳链(并且可选地,一起可以形成一个 C
2
桥),u 和 v 独立地为 0-3 的整数,使得它们的和为 3 到 5,R
2
为杂环烷基,R
1
和 R
3
如本文所定义。还公开了使用公式 I 的化合物治疗疼痛的方法。
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme
作者:Matthew M. Hamilton、Faika Mseeh、Timothy J. McAfoos、Paul G. Leonard、Naphtali J. Reyna、Angela L. Harris、Alan Xu、Michelle Han、Michael J. Soth、Barbara Czako、Jay P. Theroff、Pijus K. Mandal、Jason P. Burke、Brett Virgin-Downey、Alessia Petrocchi、Dana Pfaffinger、Norma E. Rogers、Connor A. Parker、Simon S. Yu、Yongying Jiang、Stephan Krapp、Alfred Lammens、Graham Trevitt、Martin R. Tremblay、Keith Mikule、Keith Wilcoxen、Jason B. Cross、Philip Jones、Joseph R. Marszalek、Richard T. Lewis
DOI:10.1021/acs.jmedchem.1c00679
日期:2021.8.12
Indoleamine2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a potential immunotherapeutic target in oncology. We developed a class of inhibitors with a conformationally constrained bicyclo[3.1.0]hexane core. These potently inhibited IDO1 in a cellular context by binding to the apoenzyme